The first among Indian pharmaceutical companies to realise and embrace the importance of innovation, we invest 6–8% of global revenues annually into Research and Development (R&D). With a team of over 2,900 R&D personnel with strong intellectual capabilities in formulations, process chemistry, and analytical development, our strength lies in developing generics and technologically complex products. We specialize in differentiated products including liposomal drugs, inhalers, lyophilized injections, nasal sprays, and controlled-release dosage forms, showcasing our strong focus on innovation.
Recent Posts
- Sun Pharma reports Q1FY26 results
- Sun Pharma’s Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint
- Sun Pharma Announces Launch of LEQSELVI™ (deuruxolitinib) in the United States for the Treatment of Severe Alopecia Areata
- Sun Pharma Brings Back Its #SecondBirthDate Campaign on National Doctors’ Day
- Sun Pharma appoints Kirti Ganorkar as the Managing Director; Dilip Shanghvi to continue as the Executive Chairman of the Board
Recent Comments